Clinical nanoparticle imaging agents: Thakor and colleagues focus on nanoparticles used in human medical imaging, with an emphasis on radionuclide and MR imaging, as well as newer agents for theranostic and multimodal applications.
Page 1833
α-Radiotherapy for mCRPC: Oyen and de Bono provide perspective on current therapeutic experience with α-emitting agents and preview an article in this issue of JNM on a 225Ac-labeled prostate-specific membrane antigen in metastatic castration-resistant prostate cancer.
Page 1838
CRT response prognosis: Miller and colleagues review an article in this month’s JNM on a novel radionuclide approach to quantitative prediction of response to cardiac resynchronization therapy in patients with heart failure.
Page 1840
Early prediction in HNSCC: Wong and colleagues determine the value of early assessment (1 cycle of induction chemotherapy) with 18F-FDG PET/CT and diffusion-weighted MR imaging for response to radical chemoradiotherapy in locally advanced head and neck squamous cell carcinoma.
Page 1843
18F-FLT PET in NENs: Johnbeck and colleagues investigate 18F-FLT PET as a prognostic marker for neuroendocrine neoplasms and compare results with those from 18F-FDG PET and the Ki-67 proliferation index.
Page 1851
89Zr-IAB2M minibody PC imaging: Pandit-Taskar and colleagues report on a phase I dose-escalation study with 89Zr-desferrioxamine-IAB2 M, an anti–prostate-specific membrane antigen minibody, in patients with metastatic prostate cancer.
Page 1858
Preanalytical study of bone scan index: Anand and colleagues develop and perform preanalytical studies to assess the impact of variability in scanning speed and vendor-specific γ-cameras on reproducibility and accuracy of the automated bone scan index.
Page 1865
18F-NaF PET repeatability: Lin and colleagues detail the repeatability of 18F-NaF PET–derived SUV imaging metrics in individual bone lesions from patients with castration-resistant prostate cancer and multiple metastases.
Page 1872
Optimizing data for CRT selection: Badhwar and colleagues describe a novel scintigraphic method using new parameters of mechanical left ventricular dyssynchrony and correlate results with outcomes in heart failure patients with reduced ejection fraction receiving cardiac resynchronization therapy.
Page 1880
SPECT and absolute MBF: Nkoulou and colleagues compare K1 uptake rate constants, as surrogates of absolute myocardial blood flow, and myocardial flow reserve index as assessed with a cadmium–zinc–telluride SPECT camera.
Page 1887
Assessing attenuation-corrected MPI: Huang and colleagues report on a systematic review and meta-analysis to determine whether attenuation correction improves diagnostic performance in myocardial perfusion imaging with SPECT, using coronary angiography as a reference standard.
Page 1893
PET for prognostic stratification in ILD: Nobashi and colleagues explore the clinical and prognostic utility of 18F-FDG PET/CT in patients with interstitial lung disease by investigating relationships between PET/CT parameters and clinical indicators.
Page 1899
Imaging HAM brain inflammation: Dimber and colleagues use PET with 11C-PBR28, a specific 18-kDa translocator protein ligand, and T1- and diffusion-weighted MR to image the brains of patients with human T-lymphotropic virus type 1–associated myelopathy.
Page 1905
Nuclear imaging in classic FUO: Takeuchi and colleagues systematically review reports on test performance, diagnostic yield, and management decision impact of nuclear imaging in patients with classic fever of unknown origin.
Page 1913
11C-metformin imaging: Gormsen and colleagues extend previous preclinical findings to report on first-in-human 11C-metformin PET dosimetry, biodistribution, and tissue kinetics.
Page 1920
ZTE-AC for brain PET/MR: Sekine and colleagues evaluate the clinical feasibility of PET/MR attenuation correction based on fast zero-echo-time MR imaging by comparing it with default atlas-based attenuation correction on a clinical PET/MR scanner.
Page 1927
Task-specific glucose metabolism: Hahn and colleagues validate a novel PET approach to assessing baseline cerebral glucose metabolism and task-specific changes in a single measurement with a constant infusion of 18F-FDG.
Page 1933
225Ac-PSMA-617 prostate cancer therapy: Kratochwil and colleagues report on results from the first 2 patients treated with this α-radionuclide–labeled prostate-specific membrane antigen ligand in advanced stages of prostate cancer.
Page 1941
11C-CUMI-101 and α1-adrenoceptors: Shrestha and colleagues describe assays of 11C-CUMI-101 binding to α1-adrenoceptors in vivo in the human cerebellum and in vitro in human, monkey, and rat cerebellum.
Page 1945
GEP NET imaging: Deroose and colleagues provide an educational overview of current and developing theranostic approaches to gastroenteropancreatic neuroendocrine tumors, including both primary and metastatic lesions.
Page 1949
Gastrointestinal sensitivity to radioembolization: Pasciak and colleagues perform an analysis of the effect of 90Y radioembolization in a porcine model at different absorbed-dose endpoints to elucidate dosimetric thresholds for toxicity associated with the procedure.
Page 1957
Preclinical intratherapeutic PET: Mellhammar and colleagues test the feasibility of performing intratherapeutic PET on 3 preclinical systems using 22Na point sources and phantoms filled with 18F, 99mTc, or 177Lu.
Page 1964
Perfusion study of NHL xenograft models: Mendler and colleagues characterize 2 non-Hodgkin lymphoma subtypes with comparable CD20 expression and metabolism as part of a search for preclinical animal models to evaluate tumor heterogeneity and hemodynamics in targeted antibody treatments.
Page 1971
18F-SFB PSMA for prostate cancer imaging: Harada and colleagues evaluate 4 new prostate-specific membrane antigen probes using succinimidyl 4-18F-fluorobenzoate, a rapid and effective labeling agent, in vitro and in PET imaging in human prostate cancer xenograft–bearing mice.
Page 1978
11C-methionine and myocarditis: Maya and colleagues explore the potential of radiolabeled methionine to assess myocardial inflammatory activity in a rat model of experimental autoimmune myocarditis.
Page 1985
GIRLRG peptide for tumor-targeting: Kapoor and colleagues evaluate the novel GIRLRG peptide, which specifically targets glucose-regulated protein 78, for cancer-specific binding in vitro and noninvasive tumor imaging in vivo.
Page 1991
3D-printed kidney dosimetry phantoms: Tran-Gia and colleagues demonstrate the potential of 3D printing techniques for quantitative SPECT/CT imaging with a set of kidney dosimetry phantoms and their spheric counterparts.
Page 1998
64Cu-ATSM and hypoxic plaque: Nie and colleagues determine the feasibility of 64Cu-ATSM PET detection of hypoxia in a rabbit model of atherosclerosis imaged on a simultaneous PET/MR scanner, using MR for both attenuation correction and depiction of lesion location.
Page 2006
Induced PSCs and ischemic injury: Wu and colleagues investigate in vivo dynamic metabolic changes after transplantation of induced pluripotent stem cells and their derived enriched cardiomyocytes in a rat model of ischemic injury.
Page 2012
International PET/MR practice: Fendler and colleagues report on an operational and use survey of PET/MR imaging practices from 39 international sites.
Page 2016
Published studies and FDA approvals: Rieves and Jacobs summarize precedents for FDA approval of imaging agents using effectiveness data from publications, FDA guidance, and experience in reviewing publications, with a checklist for preparing reports on exploratory clinical studies.
Page 2022
- © 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Jump to section
Related Articles
Cited By...
- No citing articles found.